Treatment of Leg Telangiectasias With Nd:YAG 1064nm

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01118390

Enrollment

Registered

2010-05-06

Start date

2009-08-31

Completion date

2010-07-31

Last updated

2010-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Telangiectasias

Keywords

telangiectasias, leg, sclerotherapy, laser, glycose

Brief summary

Studying the results of treatment of dilated vessels of the lower limbs with laser, and compare them to those obtained with sclerotherapy.

Interventions

DEVICELaser Nd:YAG 1064nm

Patients with leg telangiectasias are treated with 3 sessions of Nd:YAG 1064nm, with 14 days interval

OTHERSclerotherapy

Patients with leg telangiectasias are treated with 3 sessions of sclerotherapy, with 14 days interval

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 60 Years

Healthy volunteers

Yes

Inclusion criteria

* Patients with leg telangiectasias

Exclusion criteria

* Arterial disease * Varices * Diabetes

Design outcomes

Primary

Measure	Time frame	Description
treatment of leg telangiectasias	first day	Patients respond after treatment a questionnaire about satisfaction for both the laser and for conventional sclerotherapy.
Treatment of telangiectasias	1 month	Patients respond after treatment a questionnaire about satisfaction for both the laser and for conventional sclerotherapy.

Secondary

Measure	Time frame	Description
Presence of adverse effects	after 1 month	Patients are monitored to adverse effects such as blemishes, scars and ulcers
Pain Scores on the Visual Analog Scale	After 1 month	Patients evaluate pain on the Visual Analog Scale

Countries

Brazil

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026